Glucotrack, Inc. Files 8-K with Financial Updates

Ticker: GCTK · Form: 8-K · Filed: Apr 16, 2025 · CIK: 1506983

Sentiment: neutral

Topics: 8-K, financial-statements, regulation-fd

TL;DR

Glucotrack (GCTK) filed an 8-K on 4/16/25 covering Reg FD and financials.

AI Summary

Glucotrack, Inc. filed an 8-K on April 16, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing confirms the company's name as Glucotrack, Inc., incorporated in Delaware, with its principal executive offices located in Rutherford, NJ.

Why It Matters

This 8-K filing provides an update on Glucotrack, Inc.'s regulatory disclosures and financial statements, which are important for investors to assess the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial statements and regulatory information, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What specific financial statements are being filed with this 8-K?

The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the provided text.

What is the primary purpose of this 8-K filing for Glucotrack, Inc.?

The primary purpose is to provide a Regulation FD Disclosure and to file Financial Statements and Exhibits as of April 16, 2025.

When was Glucotrack, Inc. previously known as Integrity Applications, Inc.?

The company was formerly known as Integrity Applications, Inc. prior to a name change on December 3, 2010.

What is Glucotrack, Inc.'s SIC code?

Glucotrack, Inc.'s Standard Industrial Classification (SIC) code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

What is the SEC file number for Glucotrack, Inc.?

The SEC file number for Glucotrack, Inc. is 001-41141.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2025 regarding Glucotrack, Inc. (GCTK).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing